AR059907A2 - Proteina de fusion ob, secuencia de acido nucleico que codifica dicha proteina, vector que contiene dicha secuencia, proceso para producir dicha proteina, composicion farmaceutica que contiene dicha proteina y uso de dicha proteina para fabricar un medicamento - Google Patents
Proteina de fusion ob, secuencia de acido nucleico que codifica dicha proteina, vector que contiene dicha secuencia, proceso para producir dicha proteina, composicion farmaceutica que contiene dicha proteina y uso de dicha proteina para fabricar un medicamentoInfo
- Publication number
- AR059907A2 AR059907A2 ARP070101065A ARP070101065A AR059907A2 AR 059907 A2 AR059907 A2 AR 059907A2 AR P070101065 A ARP070101065 A AR P070101065A AR P070101065 A ARP070101065 A AR P070101065A AR 059907 A2 AR059907 A2 AR 059907A2
- Authority
- AR
- Argentina
- Prior art keywords
- protein
- amino acids
- amino acid
- acid sequence
- truncated
- Prior art date
Links
- 102000004169 proteins and genes Human genes 0.000 title abstract 10
- 108090000623 proteins and genes Proteins 0.000 title abstract 10
- 108020001507 fusion proteins Proteins 0.000 title abstract 3
- 108091028043 Nucleic acid sequence Proteins 0.000 title abstract 2
- 150000007523 nucleic acids Chemical group 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 229940024606 amino acid Drugs 0.000 abstract 18
- 150000001413 amino acids Chemical class 0.000 abstract 17
- 102000016267 Leptin Human genes 0.000 abstract 10
- 108010092277 Leptin Proteins 0.000 abstract 10
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 6
- 239000000126 substance Substances 0.000 abstract 3
- 102000037865 fusion proteins Human genes 0.000 abstract 2
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 abstract 2
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 abstract 2
- 108060003951 Immunoglobulin Proteins 0.000 abstract 1
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 abstract 1
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000002068 genetic effect Effects 0.000 abstract 1
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 abstract 1
- 102000018358 immunoglobulin Human genes 0.000 abstract 1
- 125000000741 isoleucyl group Chemical group [H]N([H])C(C(C([H])([H])[H])C([H])([H])C([H])([H])[H])C(=O)O* 0.000 abstract 1
- 229920003169 water-soluble polymer Polymers 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Diabetes (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
- Wood Science & Technology (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Plant Pathology (AREA)
- Child & Adolescent Psychology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Toxicology (AREA)
- Vascular Medicine (AREA)
- Oncology (AREA)
- Heart & Thoracic Surgery (AREA)
Abstract
Una proteína de fusion OB, secuencia de ácido nucleico que codifica dicha proteína, vector que contiene dicha secuencia, proceso para producir dicha proteína, composicion farmacéutica que contiene dicha proteína y uso de dicha proteína para fabricar un medicamento. En particular, se relaciona con una proteína de fusion genética o química que comprende la region de inmunoglobulina de Fc, derivado de análogo fusionada a la porcion de terminal N de la proteína OB, derivado o análogo. Reivindicacion 1: Una proteína que tiene una formula seleccionada del grupo formado por: R1-R2 y R1-L-R2, caracterizada porque R1 es una region Fc de una inmunoglobulina, R2 es una proteína OB, y L es un enlazador, y donde R2 es seleccionada del grupo formado por: (a) la secuencia de aminoácidos 1-146 segun se indica en SEQ. ID. N°.:3 o SEQ ID. N°.: 6; (b) la secuencia de aminoácidos 1-146 segun se indica en SEQ. ID. NO.: 6 que tiene un residuo lisina en la posicion 35 y un residuo isoleucina en la posicion 74; (c) la secuencia de aminoácidos de la sub-parte (b) que tiene un aminoácido diferente sustituido en una o más de las siguientes posiciones (usando la numeracion segun SEQ. ID. N°.: 6): 4, 8, 32, 33, 35, 48, 50, 53, 60, 64, 66, 67, 68, 71, 74, 77, 78, 89, 97, 100, 102, 105, 106, 107, 108, 111, 112, 118, 136, 138, 142 y 145; (d) la secuencia de aminoácidos de las sub-partes (a), (b) o (c) optativamente sin un residuo glutaminilo en la posicion 28; (e) la secuencia de aminoácidos de las sub-partes (a), (b), (c) o (d) que tiene un residuo metionilo en el N terminal; (f) una proteína OB truncada seleccionada entre (usando la numeracion de SEQ. ID. N°.: 6: que tiene un residuo lisina en la posicion 74): (i) aminoácidos 98-146; (ii) aminoácidos 1-32; (iii) aminoácidos 40-116; (iv) aminoácidos 1-99 y 112-146; (v) aminoácidos 1-99 y 112-146 que tienen uno o más de los aminoácidos 100-111 ubicados secuencialmente entre los aminoácidos 99 y 112; y, (vi) la proteína OB truncada de la sub-parte (f) (i) que tiene uno o más de los aminoácidos 100, 102, 105, 106, 107, 108, 111, 118, 136, 138, 142, y 145 sustituidos con otro aminoácido; (vii) la proteína OB truncada de la sub-parte (f) (ii) que tiene uno o más de los aminoácidos 4, 8 y 32 sustituidos con otro aminoácido; (viii) la proteína OB truncada de la sub-parte (f) (iii) que tiene uno o más aminoácidos 50, 53, 60, 64, 66, 67, 68, 71, 74, 77, 78, 89, 97, 100, 102, 105, 106, 107, 108, 111 y 112 reemplazados con otro aminoácido; (ix) la proteína OB truncada de la sub-parte (f) (iv) que tiene uno o más aminoácidos 4, 8, 32, 33, 35, 48, 50, 53, 60, 64, 66, 67, 68, 71, 74, 77, 78, 89, 97, 112, 118, 136, 138, 142, y 145 reemplazado con otro aminoácido; y (x) la proteína OB truncada de la sub-parte (f) (v) que tiene uno o más de los aminoácidos 4, 32, 33, 35, 48, 50, 53, .60, 64, 66, 67, 68, 71, 74, 77, 78, 89, 97, 100, 102, 105, 106, 107, 108, 111, 112, 118, 136, 138, 142, y 145 reemplazado con otro 5 aminoácido; (xi) la proteína OB truncada de las sub-partes (f) (i)-(x) que tiene un residuo metionilo en el N terminal; (g) la proteína OB de cualquiera de las sub-partes (a) a (f) comprendiendo una porcion química conectada a la porcion de proteína, donde la porcion química es un polímero soluble en agua.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US77097396A | 1996-12-20 | 1996-12-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR059907A2 true AR059907A2 (es) | 2008-05-07 |
Family
ID=25090296
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP970105894A AR009436A1 (es) | 1996-12-20 | 1997-12-16 | UNA PROTEíNA DE FUSIoN FC-OB, UNA SECUENCIA DE ÁCIDO NUCLEICO QUE LA CODIFICA, UN VECTOR, PROCEDIMIENTO DE PREPARACIoN, COMPOSICIONES FARMACÉUTICAS Y USOS. |
| ARP070101065A AR059907A2 (es) | 1996-12-20 | 2007-03-16 | Proteina de fusion ob, secuencia de acido nucleico que codifica dicha proteina, vector que contiene dicha secuencia, proceso para producir dicha proteina, composicion farmaceutica que contiene dicha proteina y uso de dicha proteina para fabricar un medicamento |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP970105894A AR009436A1 (es) | 1996-12-20 | 1997-12-16 | UNA PROTEíNA DE FUSIoN FC-OB, UNA SECUENCIA DE ÁCIDO NUCLEICO QUE LA CODIFICA, UN VECTOR, PROCEDIMIENTO DE PREPARACIoN, COMPOSICIONES FARMACÉUTICAS Y USOS. |
Country Status (25)
| Country | Link |
|---|---|
| EP (2) | EP0954588B1 (es) |
| JP (2) | JP4175668B2 (es) |
| KR (1) | KR100937550B1 (es) |
| CN (1) | CN1195858C (es) |
| AR (2) | AR009436A1 (es) |
| AT (1) | ATE351910T1 (es) |
| AU (1) | AU5606098A (es) |
| BG (1) | BG64288B1 (es) |
| BR (1) | BR9713755A (es) |
| CA (1) | CA2275183A1 (es) |
| CZ (1) | CZ298203B6 (es) |
| DE (1) | DE69737266T2 (es) |
| DK (1) | DK0954588T3 (es) |
| EA (2) | EA004790B1 (es) |
| ES (1) | ES2280083T3 (es) |
| HU (1) | HU227088B1 (es) |
| IL (1) | IL130396A (es) |
| NO (2) | NO324506B1 (es) |
| NZ (1) | NZ514145A (es) |
| PL (1) | PL194159B1 (es) |
| PT (1) | PT954588E (es) |
| RS (1) | RS49927B (es) |
| SK (1) | SK287578B6 (es) |
| WO (1) | WO1998028427A1 (es) |
| ZA (1) | ZA9711239B (es) |
Families Citing this family (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6936439B2 (en) | 1995-11-22 | 2005-08-30 | Amgen Inc. | OB fusion protein compositions and methods |
| US20030040467A1 (en) | 1998-06-15 | 2003-02-27 | Mary Ann Pelleymounter | Ig/ob fusions and uses thereof. |
| EP1285664B1 (en) * | 1995-11-22 | 2010-01-20 | Amgen Inc. | Methods of increasing lean tissue mass using OB protein compositions |
| US6620413B1 (en) | 1995-12-27 | 2003-09-16 | Genentech, Inc. | OB protein-polymer chimeras |
| US6541604B1 (en) | 1996-01-08 | 2003-04-01 | Genentech, Inc. | Leptin receptor having a WSX motif |
| US20050019325A1 (en) | 1996-01-08 | 2005-01-27 | Carter Paul J. | WSX receptor agonist antibodies |
| US7074397B1 (en) | 1996-01-08 | 2006-07-11 | Genentech, Inc. | Method for enhancing proliferation or differentiation of a cell using ob protein |
| ES2183351T3 (es) * | 1997-04-17 | 2003-03-16 | Amgen Inc | Composicones que comprenden conjugados de proteina ob humana activa estable con una cadena fc de inmunoglobulinas y metodos. |
| US20020019352A1 (en) * | 1997-04-17 | 2002-02-14 | David N. Brems | Stable, active, human ob protein compositions and methods |
| WO1999029732A2 (en) | 1997-12-08 | 1999-06-17 | Lexigen Pharmaceuticals Corporation | Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation |
| NZ506839A (en) | 1998-03-09 | 2003-05-30 | Zealand Pharma As | Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis |
| US6420339B1 (en) | 1998-10-14 | 2002-07-16 | Amgen Inc. | Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility |
| ATE348163T1 (de) | 1998-10-23 | 2007-01-15 | Amgen Inc | Thrombopoietin substitute |
| US7488590B2 (en) | 1998-10-23 | 2009-02-10 | Amgen Inc. | Modified peptides as therapeutic agents |
| US6660843B1 (en) † | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
| US7067110B1 (en) | 1999-07-21 | 2006-06-27 | Emd Lexigen Research Center Corp. | Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens |
| WO2001010912A1 (en) | 1999-08-09 | 2001-02-15 | Lexigen Pharmaceuticals Corp. | Multiple cytokine-antibody complexes |
| US8106098B2 (en) | 1999-08-09 | 2012-01-31 | The General Hospital Corporation | Protein conjugates with a water-soluble biocompatible, biodegradable polymer |
| JP2003514552A (ja) | 1999-11-12 | 2003-04-22 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | 改善された性質を有するエリトロポエチンの形態 |
| US6808902B1 (en) | 1999-11-12 | 2004-10-26 | Amgen Inc. | Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules |
| WO2001058957A2 (en) | 2000-02-11 | 2001-08-16 | Lexigen Pharmaceuticals Corp. | Enhancing the circulating half-life of antibody-based fusion proteins |
| MXPA02010351A (es) * | 2000-04-21 | 2003-04-25 | Amgen Inc | Antagonistas de integrina/adhesion. |
| US20020090646A1 (en) * | 2000-05-03 | 2002-07-11 | Amgen Inc. | Calcitonin-related molecules |
| US6677136B2 (en) * | 2000-05-03 | 2004-01-13 | Amgen Inc. | Glucagon antagonists |
| US7517526B2 (en) | 2000-06-29 | 2009-04-14 | Merck Patent Gmbh | Enhancement of antibody-cytokine fusion protein mediated immune responses by combined treatment with immunocytokine uptake enhancing agents |
| JP4279554B2 (ja) | 2001-02-19 | 2009-06-17 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｔ細胞エピトープの識別方法および低減された免疫原性を有する分子の製造方法 |
| EP1366067B1 (en) | 2001-03-07 | 2012-09-26 | Merck Patent GmbH | Expression technology for proteins containing a hybrid isotype antibody moiety |
| WO2002079415A2 (en) | 2001-03-30 | 2002-10-10 | Lexigen Pharmaceuticals Corp. | Reducing the immunogenicity of fusion proteins |
| JP2002306163A (ja) * | 2001-04-11 | 2002-10-22 | Chemo Sero Therapeut Res Inst | 大腸菌を宿主とする遺伝子組換えヒトトロンビンの調製方法 |
| DE60239454D1 (de) | 2001-05-03 | 2011-04-28 | Merck Patent Gmbh | Rekombinanter, tumorspezifischer antikörper und dessen verwendung |
| JP2005506994A (ja) | 2001-10-22 | 2005-03-10 | アムジェン インコーポレイテッド | ヒト脂肪組織萎縮症を処置するためのレプチンの使用および該処置のための素因決定方法 |
| ATE542137T1 (de) | 2001-12-04 | 2012-02-15 | Merck Patent Gmbh | Immunocytokine mit modulierter selektivität |
| WO2003077847A2 (en) | 2002-03-12 | 2003-09-25 | Merck & Co., Inc. | Substituted amides |
| US20030191056A1 (en) | 2002-04-04 | 2003-10-09 | Kenneth Walker | Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins |
| BRPI0317376B8 (pt) | 2002-12-17 | 2021-05-25 | Merck Patent Gmbh | proteína de fusão de anticorpo-il2 designada como hu14.18-il2, usos da mesma, vetor e composição farmacêutica |
| JP3936673B2 (ja) * | 2003-06-02 | 2007-06-27 | 国立大学法人群馬大学 | Ｃｄ４７部分ペプチドと抗ｓｈｐｓ−１モノクロナール抗体 |
| EP1699822B1 (en) | 2003-12-30 | 2008-04-23 | MERCK PATENT GmbH | Il-7 fusion proteins with antibody portions, their preparation and their use |
| JP2007517506A (ja) | 2004-01-05 | 2007-07-05 | イーエムディー・レキシゲン・リサーチ・センター・コーポレーション | 標的化用化合物 |
| US8076288B2 (en) | 2004-02-11 | 2011-12-13 | Amylin Pharmaceuticals, Inc. | Hybrid polypeptides having glucose lowering activity |
| US8603969B2 (en) | 2004-02-11 | 2013-12-10 | Amylin Pharmaceuticals, Llc | Pancreatic polypeptide family motifs and polypeptides comprising the same |
| CA2572765C (en) | 2004-07-08 | 2013-05-21 | Amgen Inc. | Compound having improved bioefficiency when administered in a multidose regimen |
| AU2005270918B2 (en) | 2004-08-03 | 2011-03-03 | Innate Pharma S.A. | Therapeutic and diagnostic methods and compositions targeting 4Ig-B7-H3 and its counterpart NK cell receptor |
| US7442778B2 (en) | 2004-09-24 | 2008-10-28 | Amgen Inc. | Modified Fc molecules |
| US8394765B2 (en) | 2004-11-01 | 2013-03-12 | Amylin Pharmaceuticals Llc | Methods of treating obesity with two different anti-obesity agents |
| US20090156474A1 (en) | 2004-11-01 | 2009-06-18 | Amylin Pharmaceuticals, Inc. | Methods for treating obesity and obesity related diseases and disorders |
| RU2437893C2 (ru) | 2004-12-09 | 2011-12-27 | Мерк Патент Гмбх | Варианты il-7 со сниженной иммуногенностью |
| JP2009504681A (ja) * | 2005-08-11 | 2009-02-05 | アミリン・ファーマシューティカルズ，インコーポレイテッド | 選択可能な特性を有するハイブリッドポリペプチド |
| US8008453B2 (en) | 2005-08-12 | 2011-08-30 | Amgen Inc. | Modified Fc molecules |
| EP1941043B1 (en) | 2005-10-21 | 2011-04-13 | F. Hoffmann-La Roche AG | Method for the recombinant expression of a polypeptide |
| AR059193A1 (es) | 2006-01-31 | 2008-03-12 | Bayer Schering Pharma Ag | Modulacion de la actividad de mdl-1 para el tratamiento de enfermedades inflamatorias |
| WO2009149379A2 (en) | 2008-06-05 | 2009-12-10 | Regents Of The University Of Michigan | Use of leptin for the treatment of fatty liver diseases and conditions |
| WO2010121766A1 (en) | 2009-04-22 | 2010-10-28 | Merck Patent Gmbh | Antibody fusion proteins with modified fcrn binding sites |
| WO2011020047A1 (en) | 2009-08-14 | 2011-02-17 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Use of il-15 to increase thymic output and to treat lymphopenia |
| ES2630031T3 (es) | 2010-09-28 | 2017-08-17 | Aegerion Pharmaceuticals, Inc. | Un polipéptido de leptina pinnípedo-humano quimérico con solubilidad aumentada |
| ES2732475T3 (es) | 2011-07-08 | 2019-11-22 | Aegerion Pharmaceuticals Inc | Polipéptidos modificados por ingeniería genética que tienen una duración potenciada de la acción y una inmunogenicidad reducida |
| PL2764565T3 (pl) | 2011-10-05 | 2023-06-05 | Oned Material, Inc. | Materiały aktywne z nanostrukturami krzemowymi do baterii litowo-jonowych oraz powiązane z nimi procesy, kompozycje, komponenty i urządzenia |
| CN111529535A (zh) | 2012-09-27 | 2020-08-14 | 儿童医学中心公司 | 用于治疗肥胖症的化合物和其使用方法 |
| PL3074033T3 (pl) | 2013-11-26 | 2019-08-30 | The Children's Medical Center Corporation | Związki do leczenia otyłości i sposoby ich zastosowania |
| US20170209408A1 (en) | 2014-04-03 | 2017-07-27 | The Children's Medical Center Corporation | Hsp90 inhibitors for the treatment of obesity and methods of use thereof |
| US10775386B2 (en) | 2016-09-12 | 2020-09-15 | Aegerion Pharmaceuticals, Inc. | Methods of detecting anti-leptin neutralizing antibodies |
| CN110396133B (zh) | 2018-04-25 | 2021-07-23 | 免疫靶向有限公司 | 一种以白介素12为活性成分的融合蛋白型药物前体 |
| CN110183530A (zh) | 2019-06-21 | 2019-08-30 | 深圳市亚辉龙生物科技股份有限公司 | 瘦素免疫原、杂交瘤细胞、单克隆抗体、多克隆抗体及应用 |
| CN112618698B (zh) * | 2019-10-08 | 2021-10-08 | 北京东方百泰生物科技股份有限公司 | 一种人白细胞介素10-Fc融合蛋白的注射制剂 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| EP0770135A1 (en) * | 1994-07-29 | 1997-05-02 | Smithkline Beecham Plc | Novel compounds |
| US6309853B1 (en) * | 1994-08-17 | 2001-10-30 | The Rockfeller University | Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof |
| JPH0870875A (ja) * | 1994-09-05 | 1996-03-19 | Tosoh Corp | 組換えアルカリフォスファタ−ゼ融合タンパク質 |
| GB9511935D0 (en) * | 1995-06-13 | 1995-08-09 | Smithkline Beecham Plc | Novel compound |
| EP1285664B1 (en) * | 1995-11-22 | 2010-01-20 | Amgen Inc. | Methods of increasing lean tissue mass using OB protein compositions |
| DE69632546T2 (de) * | 1995-12-27 | 2005-06-30 | Genentech, Inc., South San Francisco | Ob proteinderivate mit verlängerter halbwertzeit |
-
1997
- 1997-12-11 KR KR1019997005618A patent/KR100937550B1/ko not_active Expired - Fee Related
- 1997-12-11 WO PCT/US1997/023183 patent/WO1998028427A1/en not_active Ceased
- 1997-12-11 EP EP97952464A patent/EP0954588B1/en not_active Expired - Lifetime
- 1997-12-11 AT AT97952464T patent/ATE351910T1/de active
- 1997-12-11 PL PL334242A patent/PL194159B1/pl not_active IP Right Cessation
- 1997-12-11 AU AU56060/98A patent/AU5606098A/en not_active Abandoned
- 1997-12-11 BR BR9713755-3A patent/BR9713755A/pt active Search and Examination
- 1997-12-11 CA CA002275183A patent/CA2275183A1/en not_active Abandoned
- 1997-12-11 DK DK97952464T patent/DK0954588T3/da active
- 1997-12-11 EA EA199900575A patent/EA004790B1/ru not_active IP Right Cessation
- 1997-12-11 CN CNB971818177A patent/CN1195858C/zh not_active Expired - Fee Related
- 1997-12-11 DE DE69737266T patent/DE69737266T2/de not_active Expired - Lifetime
- 1997-12-11 PT PT97952464T patent/PT954588E/pt unknown
- 1997-12-11 EP EP06024946A patent/EP1835030A1/en not_active Withdrawn
- 1997-12-11 ES ES97952464T patent/ES2280083T3/es not_active Expired - Lifetime
- 1997-12-11 RS YUP-279/99A patent/RS49927B/sr unknown
- 1997-12-11 NZ NZ514145A patent/NZ514145A/en not_active IP Right Cessation
- 1997-12-11 JP JP52889698A patent/JP4175668B2/ja not_active Expired - Fee Related
- 1997-12-11 CZ CZ0203699A patent/CZ298203B6/cs not_active IP Right Cessation
- 1997-12-11 IL IL130396A patent/IL130396A/en not_active IP Right Cessation
- 1997-12-11 EA EA200100216A patent/EA004791B1/ru not_active IP Right Cessation
- 1997-12-11 SK SK774-99A patent/SK287578B6/sk not_active IP Right Cessation
- 1997-12-11 HU HU0000302A patent/HU227088B1/hu not_active IP Right Cessation
- 1997-12-15 ZA ZA9711239A patent/ZA9711239B/xx unknown
- 1997-12-16 AR ARP970105894A patent/AR009436A1/es active IP Right Grant
-
1999
- 1999-06-08 NO NO19992779A patent/NO324506B1/no not_active IP Right Cessation
- 1999-06-23 BG BG103522A patent/BG64288B1/bg unknown
-
2007
- 2007-03-16 AR ARP070101065A patent/AR059907A2/es unknown
- 2007-03-16 NO NO20071415A patent/NO325096B1/no not_active IP Right Cessation
-
2008
- 2008-05-29 JP JP2008140707A patent/JP4659068B2/ja not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR059907A2 (es) | Proteina de fusion ob, secuencia de acido nucleico que codifica dicha proteina, vector que contiene dicha secuencia, proceso para producir dicha proteina, composicion farmaceutica que contiene dicha proteina y uso de dicha proteina para fabricar un medicamento | |
| Wen et al. | Identification of a signal for rapid export of proteins from the nucleus | |
| Geisler et al. | Proteinchemical characterization of three structurally distinct domains along the protofilament unit of desmin 10 nm filaments | |
| ATE170219T1 (de) | Rekombinanter abkömmling des menschlichen faktors iii | |
| ECSP064643A (es) | Proteinas de fusion de glp-1 | |
| DK168823B1 (da) | Fusionsproteiner, hvor ballastandelen består af peptider af interleukin 2, fremgangsmåde til deres fremstilling, deres anvendelse, genstruktur, der koder for et sådant fusionsprotein, vektor indeholdende en sådan genstruktur, og E. coli-celle indeholdende en sådan vektor. | |
| DE69027989D1 (de) | Il-3 MIT ZUSÄTZLICHEN CYSTEINRESTEN UND CHEMISCHE MODIFIKATIONEN DAVON | |
| KR880007734A (ko) | 폴리펩타이드 유도체 | |
| EP0722461A4 (en) | EXPRESSION OF FUSION POLYPEPTIDES TRANSPORTED OUT OF CYTOPLASM WITHOUT HEAD SEQUENCE | |
| NO20050998L (no) | DNA som koder for et biologisk aktivt fragment av baktericid/premeabilitetsokende protein fremgangsmate for fremstilling av dette, samt farmasoytisk preparat inneholdende dette | |
| SE9100799L (sv) | Rekombinant derivat av human faktor viii | |
| NO940736D0 (no) | DNA sekvenser som koder for gelonin polypeptid | |
| IL98024A0 (en) | Cd44-surface proteins,dna-sequences coding therefor,polypeptides coded by said dna sequences and diagnostic compositions containing the same | |
| KR960704041A (ko) | 사람 인터루킨-10의 효능제 및 길항제(Agonists and antagonists of human interleukin-10) | |
| US20080171697A1 (en) | Peptides Having For Example Antiangiogenic Activity and Applications Thereof In Therapeutics | |
| DE69233245D1 (de) | Verfahren zur Herstellung von Peptiden | |
| NO930428D0 (no) | Proteinstrukturen til plantetoksingelonin | |
| AR044603A1 (es) | Proteinas quimericas aisladas de lumazina sintetasa modificada para la presentacion multiple de moleculas y sus aplicaciones | |
| ES2078925T3 (es) | Proteinas de la estreptoquinasa, genes correspondientes, recombinantes plasmidicos correspondientes, transformantes correspondientes y procedimientos para su preparacion. | |
| Giudice et al. | Glycoprotein hormones: some aspects of studies of secondary and tertiary structure | |
| PE20010238A1 (es) | GEN DERIVADO DE LAWSONIA Y POLIPEPTIDOS SodC, PEPTIDOS Y PROTEINAS RELACIONADOS Y SUS USOS | |
| Wellman et al. | Secondary structure of synthetic peptides derived from the repeating unit of a giant secretory protein from Chironomus tentans | |
| PE20010239A1 (es) | Gen derivado de lawsonia y polipeptidos, peptidos y proteinas de hemolisina relacionados y sus usos | |
| CO5241360A1 (es) | Composiciones de flint y usos de estas | |
| MX2024009329A (es) | Composiciones de proteína potenciadas. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |